证券代码：301515 证券简称：港通医疗 公告编号：2025-038 四川港通医疗设备集团股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东会届次：2025年第一次临时股东会 2．股东会的召集人：公司董事会 7．出席对象： （1）在股权登记日持有公司已发行有表决权股份的股东或其代理人； 于股权登记日下午收市时在中国证券登记结算有限责任公司深圳分公司登记 在册的公司全体已发行有表决权股份的股东均有权出席本次股东会，并可以以书 面形式委托代理人出席会议和参加表决，该股东代理人不必是本公司的股东。 （2）公司董事、高级管理人员； 3．会议召开的合法、合规性：经公司第五届董事会第二次会议审议通过《关 于提议召开公司2025年第一次临时股东会的议案》，本次股东会的召集、召开程序 符合有关法律、行政法规、部门规章、规范性文件、深圳证券交易所相关业务规 则和《公司章程》的规定。 4．会议召开的日期、时间： （1）现场会议时间：2025年7月18日（星期五）下午2点 （2）网络投票时间：通 ...

Core Viewpoint - The financial performance of 港通医疗 (301515.SZ) has significantly declined in both 2024 and the first quarter of 2025, with substantial drops in revenue and net profit compared to previous periods [1][2][3]. Financial Performance Summary - For Q1 2025, the company reported revenue of 24.29 million yuan, a decrease of 68.09% year-on-year [2] - The net profit attributable to shareholders was 1.58 million yuan, down 85.25% year-on-year [2] - The net profit after excluding non-recurring items was 1.41 million yuan, a decline of 86.46% year-on-year [2] - The net cash flow from operating activities was -15.09 million yuan, compared to 37.50 million yuan in the same period last year [2] Annual Financial Results - In 2024, the company achieved revenue of 754.06 million yuan, a decrease of 10.49% compared to 2023 [3] - The net profit attributable to shareholders was 14.42 million yuan, down 82.64% year-on-year [3] - The net profit after excluding non-recurring items was 5.01 million yuan, a decline of 91.74% year-on-year [3] - The net cash flow from operating activities improved to -10.94 million yuan from -114.32 million yuan in the previous year [3] Previous Year Comparison - In 2023, the company reported revenue of 842.44 million yuan, an increase of 9.62% from 2022 [4] - The net profit attributable to shareholders was 83.10 million yuan, up 12.40% year-on-year [4] - The net profit after excluding non-recurring items was 60.63 million yuan, a decrease of 13.93% year-on-year [4] - The net cash flow from operating activities was -11.43 million yuan, compared to 49.94 million yuan in 2022 [4] IPO and Fundraising - 港通医疗 was listed on the Shenzhen Stock Exchange's ChiNext on July 25, 2023, with an issuance of 25 million shares at a price of 31.16 yuan per share [6] - The total funds raised amounted to 779 million yuan, with a net amount of 689.99 million yuan, exceeding the initial plan by 29.996 million yuan [6] - The funds are intended for the construction of a smart medical equipment production base, upgrading the R&D technology center, and supplementing working capital [6]

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Kangtong Medical, which has a high PE ratio compared to its industry peers [1][2] - As of June 16, Kangtong Medical's stock closed at 19.8 yuan, with a rolling PE ratio of 374.05, significantly higher than the industry average of 49.56 [1][2] - The company has a total market capitalization of 1.98 billion yuan, ranking 120th in the medical device industry based on PE ratio [1][2] Group 2 - Kangtong Medical's main business includes the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as clean medical equipment [1] - The company has received multiple accolades, including being recognized as a "National Specialized and Innovative Small Giant Enterprise" and a "National High-tech Enterprise" [1] - The latest financial report for Q1 2025 shows a revenue of 2,428.67 million yuan, a year-on-year decrease of 68.09%, and a net profit of 157.90 million yuan, down 85.25% [1]

Group 1 - The company held its first meeting of the fifth board of directors on June 11, 2025, with all nine directors present, and the meeting was deemed legal and effective [1][2]. - The board elected Chen Yong as the chairman of the fifth board of directors for a term of three years starting from the approval date [1][2]. - The board approved the election of committee members, including Chen Yong as the head of the strategy committee and Zhao Chen as the head of the audit committee, with all votes in favor [2]. Group 2 - The board appointed Chen Yong as the general manager, Chen Xinggen as the board secretary and deputy general manager, and several others as vice general managers and financial director, with unanimous approval [2][3]. - Chen Lijia was appointed as the securities affairs representative for a term of three years, also receiving unanimous support [3]. - The board proposed to provide a guarantee of up to 8 million yuan for the financing needs of its wholly-owned subsidiary, Sichuan Meidifa Medical Equipment Co., Ltd., with the guarantee valid for 12 months [3].

Meeting Details - The board meeting was held on June 11, 2025, with specific voting times for both network and internet voting [1] - A total of 66 shareholders and authorized representatives attended the meeting, representing 37,690,800 shares, which is 39.2436% of the total voting shares [1] Voting Results - The meeting adopted a combination of on-site and online voting, with 37,616,300 shares in favor of the proposals, accounting for the majority of the valid votes [2][3] - Among minority shareholders, 1,258,700 shares voted in favor, representing 94.4119% of the minority shareholder votes [2][3] - The total number of abstentions was 3,000 shares, with 200 shares defaulting to abstention due to non-voting [2][3] Election of Directors - The election of directors was conducted using a cumulative voting system, with results showing that several candidates were elected as non-independent directors [10][12] - Specific votes included 37,036,220 votes for one candidate, representing a significant majority of the voting shares [10] - The election results for minority shareholders indicated that 678,620 votes were cast for one candidate, which is 50.9016% of the minority shareholder votes [10] Legal Compliance - The meeting was witnessed by legal representatives from a law firm, confirming that the procedures followed were in compliance with relevant laws and regulations [13]

北京金杜（成都）律师事务所 届董事会第二十次会议决议公告》； 息披露媒体的《第四届监事会第十九次会议决议公告》； 息披露媒体的《四川港通医疗设备集团股份有限公司关于召开 2024 年年度股东会 的通知》（以下简称《股东会通知》）； 关于四川港通医疗设备集团股份有限公司 致：四川港通医疗设备集团股份有限公司 北京金杜（成都）律师事务所（以下简称本所）接受四川港通医疗设备集团股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》） 、《中华人民共和国公司法》 （以下简称《公司法》）、中国证券监督管理委员 会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境内（以 下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中国澳门 特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件和现行 有效的公司章程有关规定，指派律师出席公司于 2025 年 6 月 11 日召开的 2024 年年度股东会（以下简称本次股东会），并对本次股东会的相关事项出具本法律意 见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 限公司章程》（以下 ...

Group 1 - The company completed the election of the fifth board of directors and appointed senior management and securities affairs representative [1][2] - The fifth board of directors consists of 9 members, with a term of three years starting from the approval date of the annual shareholders' meeting [1][2] - The board includes independent directors and employee representatives, ensuring compliance with regulations regarding board composition [2] Group 2 - The senior management team includes General Manager Chen Yong, Secretary of the Board Chen Xinggen, and Chief Financial Officer Zhang Qiu [3] - The securities affairs representative is Chen Lijia, who holds relevant qualifications [3][18] - The appointed senior management and securities affairs representative will serve a term of three years [3] Group 3 - The fourth supervisory board's term has expired, and three supervisors have stepped down but will continue to work in the company [4][5] - The departing supervisors include Shi Wencong, Li Lanying, and Chen Liangping, with their shareholdings disclosed [5]

一。 特此公告。 四川港通医疗设备集团股份有限公司董事会 证券代码：301515 证券简称：港通医疗 公告编号：2025-036 四川港通医疗设备集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川港通医疗设备集团股份有限公司（以下简称"公司"）第四届董事会任 期于 2025 年 6 月 11 日届满。根据《公司法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及《公司章程》等有关规定，公司 第五届董事会由 9 名董事组成，其中 1 名为职工代表董事，由公司职工代表大会 选举产生。 公司于 2025 年 6 月 10 日在公司会议室召开了职工代表大会。经与会职工代 表认真讨论，会议选举魏勇先生为公司第五届董事会职工代表董事，职工代表董 事魏勇先生个人简历详见附件。 魏勇先生将与公司 2024 年年度股东会选举产生的 8 位董事共同组成公司第 五届董事会，任期与股东会选举产生的董事任期一致，自 2024 年年度股东会审 议通过之日起三年。魏勇先生担任职工代表董事后，公司董事会中兼任公司高 级管理人员以及由职工代表担 ...

Overview - The company plans to provide a guarantee of up to 8 million yuan for its wholly-owned subsidiary, Sichuan Meidifa Medical Equipment Co., Ltd., to support its daily operations and development needs [1][3]. Guarantee Details - The guarantee will be valid for 12 months from the date of the board's approval [1]. - The board has authorized the legal representative or designated agent to handle the necessary procedures related to the guarantee [1]. Financial Situation of the Subsidiary - As of March 31, 2025, Sichuan Meidifa Medical Equipment Co., Ltd. has total assets of 42.01 million yuan and total liabilities of 19.99 million yuan, resulting in a net asset value of 22.02 million yuan [2]. - The asset-liability ratio is reported at 47.58% [2]. - For the first quarter of 2025, the subsidiary reported an operating income of 3.07 million yuan and a net profit of 3.15 million yuan [2]. Board's Opinion - The board believes that the subsidiary has a good credit record and strong debt repayment capability, making the financial risk manageable [3]. - The guarantee is seen as beneficial for the subsidiary's operational and business development needs, enhancing its financing capacity [3]. Cumulative Guarantee Information - As of the announcement date, the total guarantee amount for the company and its subsidiaries is 8 million yuan, which is 0.62% of the company's latest audited net assets [3]. - There are no overdue guarantees or guarantees involving litigation against the company [3].

证券代码：301515 证券简称：港通医疗 公告编号：2025-035 四川港通医疗设备集团股份有限公司 关于完成董事会换届选举及聘任高级管理人 员、证券事务代表的公告 四川港通医疗设备集团股份有限公司（以下简称"公司"）于 2025 年 6 月 11 日召开职工代表大会选举产生了1名职工代表董事，并召开2024年年度股东会， 以累积投票方式审议通过了《关于董事会换届选举暨提名第五届董事会非独立董 事候选人的议案》《关于董事会换届选举暨提名第五届董事会独立董事候选人的 议案》，选举产生了公司第五届董事会董事；同日，公司召开了第五届董事会第 一次会议，审议通过了选举公司董事长、董事会各专门委员会委员及聘任公司高 级管理人员及证券事务代表等相关议案。公司第五届董事会换届选举已经完成， 现将相关情况公告如下。 一、第五届董事会及各专门委员会组成情况 （一）董事会成员 1、非独立董事：陈永先生、陈兴根先生、文再敏先生、陈叙先生、刘煜强 先生 2、职工代表董事：魏勇先生 3、独立董事：周正女士、赵尘女士、姚刚先生 公司第五届董事会成员由以上 9 名董事组成，任期三年，自 2024 年年度股 东会审议通过之日起至第五届董 ...